Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.51 |
| ▸ | MINK1 | Q8N4C8 | 4/20 | 0.51 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 5/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16798282 | 0.87 | L3MBTL1 (0.40) | MAP4K4MINK1TNIKIDO1MAPT | |
| SCHEMBL28374207 | 0.81 | KMO (0.41) | MAP4K4MAPTKMO | |
| SCHEMBL980557 | 0.81 | IDO1 (0.51) | MAP4K4IDO1ADORA2AKMOMAPK13 | |
| SCHEMBL38657570 | 0.81 | IDO1 (0.51) | MAP4K4IDO1ADORA2AKMOMAPK13 | |
| SCHEMBL2349505 | 0.80 | KMO (0.60) | MAP4K4IDO1MAPTKMO | |
| SCHEMBL447519 | 0.79 | KMO (0.64) | MAPTKMO | |
| SCHEMBL446173 | 0.79 | MEN1 (0.58) | MAP4K4MAPTKMO | |
| SCHEMBL18406257 | 0.78 | MAP4K4 (0.51) | MAP4K4MINK1TNIKIDO1MAPK1 | |
| SCHEMBL31380411 | 0.78 | KMO (0.49) | MAPTADORA2AKMO | |
| SCHEMBL29131080 | 0.78 | KMO (0.49) | MAPTADORA2AKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3494971-B1 | SALTS OF ERK INHIBITORS | GENENTECH INC (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-111777594-B | Method for preparing a medicament | 基因泰克公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11066389-B2 | Process for the manufacturing of medicaments | GENENTECH, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-112645927-A | Process for the preparation of a medicament | 基因泰克公司 | 2021-04-13 | — | — | CN | disclosed |
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-106659721-B | Process for the preparation of a medicament | 基因泰克公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-111777594-A | Process for the preparation of a medicament | 基因泰克公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-106349217-B | Serine/threonine kinase inhibitors | 阵列生物制药公司 | 2020-08-28 | — | — | CN | disclosed |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-1951730-B1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S BIO PTE LTD (SG) | 2010-05-26 | — | — | EP | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-10-15 | — | — | US | disclosed |
| CN-101365703-A | Heteroalkyl linked pyrimidine derivatives | S BIO PTE LTD (SG) | 2009-02-11 | — | — | CN | disclosed |
| WO-2008140419-A2 | PYRIDYL SUBSTITUTED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140419-A2 | PYRIDYL SUBSTITUTED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2008-11-20 | — | — | WO | disclosed |
| EP-1951730-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*Bio Pte Ltd (SG) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058628-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058628-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258886-A1 | HETEROALKYL LINKED PYRIMIDINE DERIVATIVES | TK1, TK2, DPYD | MAP4K4 279/4885MINK1 512/4885TNIK 743/4885 |
| US-11066389-B2 | Process for the manufacturing of medicaments | ARSA, F8, CYP4A11 | MAP4K4 1002/4885MINK1 3908/4885TNIK 2070/4885 |
| US-20200190061-A1 | PROCESS FOR THE MANUFACTURING OF MEDICAMENTS | ARSA, F8, CYP4A11 | MAP4K4 1002/4885MINK1 3908/4885TNIK 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.